Pharma BD Deal Intelligence
Evommune entered an exclusive license agreement with China-based Hinova Pharmaceuticals for worldwide rights outside Greater China to develop, manufacture and commercialize EVO570, an investigational oral VAV1 molecular glue degrader. Consideration comprised $20 million in cash and $10 million in pre-funded warrants, plus development, regulatory and commercial milestones of approximately $1.1 billion and tiered royalties. VAV1 expression is largely restricted to immune cells, where it acts as a key signaling protein downstream of both the T-cell and B-cell receptors. IND filings had been submitted in China and accepted in the United States, with a Phase I trial assessing safety, pharmacokinetics and target engagement scheduled to begin imminently.
← Browse all deals · How we score deals
More: 2026 deals